Latest Healthcare Research Reports

Tag: giant cell arteritis market major players

  • Giant-Cell Arteritis Market Size Projected To Increase From $1.17 Billion To $1.39 Billion During The Forecast Period

    Giant-Cell Arteritis Market Size Projected To Increase From $1.17 Billion To $1.39 Billion During The Forecast Period

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Giant-Cell Arteritis Market Growth From $1.17 Billion In 2026 To $1.39 Billion By 2030 At A CAGR Of 4.3%

    The global market for giant-cell arteritis experienced consistent expansion recently, projected to advance from a value of $1.12 billion in 2025 to $1.18 billion in 2026, reflecting a compound annual growth rate of 4.9%. This upward trajectory during the preceding period was fueled by several key factors, including a growing elderly demographic, continued reliance on corticosteroid treatments, enhancements in the quality of rheumatological care, the proliferation of hospital-based treatment options, and heightened public and medical awareness of the condition.

    The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years, reaching an estimated $1.39 billion by 2030 with a compound annual growth rate of 4.3%. This anticipated growth is fueled by several key factors including the introduction of new biologic drugs, advancements in immunological research, enhancements in diagnostic procedures, the development of individualized treatment approaches for vasculitis, and the proliferation of specialized treatment centers. During this forecast period, prominent trends will involve a greater acceptance of biologic treatments, an intensified emphasis on prompt and precise diagnosis, wider utilization of therapies that minimize corticosteroid reliance, more effective long-term patient monitoring, and heightened public awareness regarding the prevention of vision impairment.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    Giant-Cell Arteritis Market Opportunity Drivers: What Is Creating New Revenue Potential?

    The expanding focus on individualized medical approaches is anticipated to be a significant catalyst for the expansion of the giant-cell arteritis market. This trend toward personalized medicine, which centers on customizing treatments to an individual’s unique genetic makeup, lifestyle, and environmental influences, is gaining momentum thanks to breakthroughs in genomics, biotechnology, and data analysis. These advancements facilitate the development of therapies precisely targeted to a patient’s specific needs, thereby enhancing treatment effectiveness and minimizing unwanted side effects. In the context of GCA, personalized medicine offers the potential for highly specific interventions based on factors like a patient’s genetic susceptibility, immune system characteristics, and the particular way their disease presents. Indicating the widespread adoption of this methodology, the Personalized Medicine Coalition noted in February 2024 that personalized medicines represented more than a third of all new drug approvals by the FDA in 2023, marking the fourth year in a row this trend has held true. That same year saw 16 new personalized treatments greenlit by the FDA, predominantly for uncommon conditions, a notable increase from the 6 such approvals in 2022, with these 2023 approvals also including seven cancer drugs and three treatments for a range of other ailments. Consequently, the increasing prominence of tailored medical treatments is a key driver for the growth observed in the giant-cell arteritis market.

    Giant-Cell Arteritis Market Segment Analysis And Revenue Opportunities

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Giant-Cell Arteritis Market Innovation Trends Driving Future Development

    The landscape of giant-cell arteritis treatment is being enhanced by leading pharmaceutical firms introducing novel therapeutics, including biosimilars, aimed at broadening therapeutic choices and fulfilling persistent patient requirements. A biosimilar signifies a biological medicinal product that closely mirrors an existing, authorized biologic formulation, exhibiting no significant clinical disparities in its safety profile, purity, or efficacy. By way of illustration, Fresenius SE & Co. KGaA, a health sector entity headquartered in Germany, introduced Tocilizumab-aazg in the United States during April 2024, offering a new treatment avenue for chronic autoimmune conditions. This particular biosimilar has received regulatory clearance for indications encompassing rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. The validation for its utilization stemmed from findings derived from a randomized, double-blind investigation conducted in phase 1, which involved a single dose administration and parallel group design, evaluating its pharmacokinetic properties, safety observations, and immunogenic response against both United States and European reference tocilizumab products across three distinct patient cohorts.

    Giant-Cell Arteritis Market Leading Players Shaping Industry Direction

    Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

    Access The Complete Giant-Cell Arteritis Market Report:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Giant-Cell Arteritis Market Regional Analysis And Leading Geography

    North Americawas the largest region in the giant-cell arteritis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Giant-Cell Arteritis Market Size Projected To Increase From $1.17 Billion To $1.39 Billion During The Forecast Period

    Giant-Cell Arteritis Market Size Projected To Increase From $1.17 Billion To $1.39 Billion During The Forecast Period

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Giant-Cell Arteritis Market Growth From $1.17 Billion In 2026 To $1.39 Billion By 2030 At A CAGR Of 4.3%

    The global market for giant-cell arteritis experienced consistent expansion recently, projected to advance from a value of $1.12 billion in 2025 to $1.18 billion in 2026, reflecting a compound annual growth rate of 4.9%. This upward trajectory during the preceding period was fueled by several key factors, including a growing elderly demographic, continued reliance on corticosteroid treatments, enhancements in the quality of rheumatological care, the proliferation of hospital-based treatment options, and heightened public and medical awareness of the condition.

    The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years, reaching an estimated $1.39 billion by 2030 with a compound annual growth rate of 4.3%. This anticipated growth is fueled by several key factors including the introduction of new biologic drugs, advancements in immunological research, enhancements in diagnostic procedures, the development of individualized treatment approaches for vasculitis, and the proliferation of specialized treatment centers. During this forecast period, prominent trends will involve a greater acceptance of biologic treatments, an intensified emphasis on prompt and precise diagnosis, wider utilization of therapies that minimize corticosteroid reliance, more effective long-term patient monitoring, and heightened public awareness regarding the prevention of vision impairment.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    Giant-Cell Arteritis Market Opportunity Drivers: What Is Creating New Revenue Potential?

    The expanding focus on individualized medical approaches is anticipated to be a significant catalyst for the expansion of the giant-cell arteritis market. This trend toward personalized medicine, which centers on customizing treatments to an individual’s unique genetic makeup, lifestyle, and environmental influences, is gaining momentum thanks to breakthroughs in genomics, biotechnology, and data analysis. These advancements facilitate the development of therapies precisely targeted to a patient’s specific needs, thereby enhancing treatment effectiveness and minimizing unwanted side effects. In the context of GCA, personalized medicine offers the potential for highly specific interventions based on factors like a patient’s genetic susceptibility, immune system characteristics, and the particular way their disease presents. Indicating the widespread adoption of this methodology, the Personalized Medicine Coalition noted in February 2024 that personalized medicines represented more than a third of all new drug approvals by the FDA in 2023, marking the fourth year in a row this trend has held true. That same year saw 16 new personalized treatments greenlit by the FDA, predominantly for uncommon conditions, a notable increase from the 6 such approvals in 2022, with these 2023 approvals also including seven cancer drugs and three treatments for a range of other ailments. Consequently, the increasing prominence of tailored medical treatments is a key driver for the growth observed in the giant-cell arteritis market.

    Giant-Cell Arteritis Market Segment Analysis And Revenue Opportunities

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Giant-Cell Arteritis Market Innovation Trends Driving Future Development

    The landscape of giant-cell arteritis treatment is being enhanced by leading pharmaceutical firms introducing novel therapeutics, including biosimilars, aimed at broadening therapeutic choices and fulfilling persistent patient requirements. A biosimilar signifies a biological medicinal product that closely mirrors an existing, authorized biologic formulation, exhibiting no significant clinical disparities in its safety profile, purity, or efficacy. By way of illustration, Fresenius SE & Co. KGaA, a health sector entity headquartered in Germany, introduced Tocilizumab-aazg in the United States during April 2024, offering a new treatment avenue for chronic autoimmune conditions. This particular biosimilar has received regulatory clearance for indications encompassing rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. The validation for its utilization stemmed from findings derived from a randomized, double-blind investigation conducted in phase 1, which involved a single dose administration and parallel group design, evaluating its pharmacokinetic properties, safety observations, and immunogenic response against both United States and European reference tocilizumab products across three distinct patient cohorts.

    Giant-Cell Arteritis Market Leading Players Shaping Industry Direction

    Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

    Access The Complete Giant-Cell Arteritis Market Report:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Giant-Cell Arteritis Market Regional Analysis And Leading Geography

    North Americawas the largest region in the giant-cell arteritis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Giant-Cell Arteritis Market Size Projected To Increase From $1.17 Billion To $1.39 Billion During The Forecast Period

    Giant-Cell Arteritis Market Size Projected To Increase From $1.17 Billion To $1.39 Billion During The Forecast Period

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Giant-Cell Arteritis Market Growth From $1.17 Billion In 2026 To $1.39 Billion By 2030 At A CAGR Of 4.3%

    The global market for giant-cell arteritis experienced consistent expansion recently, projected to advance from a value of $1.12 billion in 2025 to $1.18 billion in 2026, reflecting a compound annual growth rate of 4.9%. This upward trajectory during the preceding period was fueled by several key factors, including a growing elderly demographic, continued reliance on corticosteroid treatments, enhancements in the quality of rheumatological care, the proliferation of hospital-based treatment options, and heightened public and medical awareness of the condition.

    The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years, reaching an estimated $1.39 billion by 2030 with a compound annual growth rate of 4.3%. This anticipated growth is fueled by several key factors including the introduction of new biologic drugs, advancements in immunological research, enhancements in diagnostic procedures, the development of individualized treatment approaches for vasculitis, and the proliferation of specialized treatment centers. During this forecast period, prominent trends will involve a greater acceptance of biologic treatments, an intensified emphasis on prompt and precise diagnosis, wider utilization of therapies that minimize corticosteroid reliance, more effective long-term patient monitoring, and heightened public awareness regarding the prevention of vision impairment.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    Giant-Cell Arteritis Market Opportunity Drivers: What Is Creating New Revenue Potential?

    The expanding focus on individualized medical approaches is anticipated to be a significant catalyst for the expansion of the giant-cell arteritis market. This trend toward personalized medicine, which centers on customizing treatments to an individual’s unique genetic makeup, lifestyle, and environmental influences, is gaining momentum thanks to breakthroughs in genomics, biotechnology, and data analysis. These advancements facilitate the development of therapies precisely targeted to a patient’s specific needs, thereby enhancing treatment effectiveness and minimizing unwanted side effects. In the context of GCA, personalized medicine offers the potential for highly specific interventions based on factors like a patient’s genetic susceptibility, immune system characteristics, and the particular way their disease presents. Indicating the widespread adoption of this methodology, the Personalized Medicine Coalition noted in February 2024 that personalized medicines represented more than a third of all new drug approvals by the FDA in 2023, marking the fourth year in a row this trend has held true. That same year saw 16 new personalized treatments greenlit by the FDA, predominantly for uncommon conditions, a notable increase from the 6 such approvals in 2022, with these 2023 approvals also including seven cancer drugs and three treatments for a range of other ailments. Consequently, the increasing prominence of tailored medical treatments is a key driver for the growth observed in the giant-cell arteritis market.

    Giant-Cell Arteritis Market Segment Analysis And Revenue Opportunities

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Giant-Cell Arteritis Market Innovation Trends Driving Future Development

    The landscape of giant-cell arteritis treatment is being enhanced by leading pharmaceutical firms introducing novel therapeutics, including biosimilars, aimed at broadening therapeutic choices and fulfilling persistent patient requirements. A biosimilar signifies a biological medicinal product that closely mirrors an existing, authorized biologic formulation, exhibiting no significant clinical disparities in its safety profile, purity, or efficacy. By way of illustration, Fresenius SE & Co. KGaA, a health sector entity headquartered in Germany, introduced Tocilizumab-aazg in the United States during April 2024, offering a new treatment avenue for chronic autoimmune conditions. This particular biosimilar has received regulatory clearance for indications encompassing rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. The validation for its utilization stemmed from findings derived from a randomized, double-blind investigation conducted in phase 1, which involved a single dose administration and parallel group design, evaluating its pharmacokinetic properties, safety observations, and immunogenic response against both United States and European reference tocilizumab products across three distinct patient cohorts.

    Giant-Cell Arteritis Market Leading Players Shaping Industry Direction

    Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

    Access The Complete Giant-Cell Arteritis Market Report:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Giant-Cell Arteritis Market Regional Analysis And Leading Geography

    North Americawas the largest region in the giant-cell arteritis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Giant Cell Arteritis Market Shift Driven by Personalized Medicine Adoption

    Giant Cell Arteritis Market Shift Driven by Personalized Medicine Adoption

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Value Of The Giant-Cell Arteritis Market Progress Between 2026 And 2030?

    The giant-cell arteritis market has experienced consistent growth in recent years. It is projected to increase from $1.12 billion in 2025 to $1.18 billion in 2026, at a compound annual growth rate (CAGR) of 4.9%. The historical expansion of this market can be attributed to an aging population, the continued reliance on corticosteroid therapy, improvements in rheumatology care, the broader availability of hospital-based treatment, and increased awareness of the disease.

    The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projected period include the approval of biologic drugs, advancements in immunology research, enhanced diagnostic procedures, tailored treatments for vasculitis, and the proliferation of specialized clinics. Key trends anticipated during the same period encompass a greater uptake of biologic therapies, a heightened emphasis on prompt and precise diagnosis, wider application of corticosteroid-reducing treatments, better long-term monitoring of the disease, and increased understanding regarding the prevention of vision loss.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Which Drivers Are Supporting The Giant-Cell Arteritis Market Growth?

    The market for giant-cell arteritis is projected to expand due to an increasing focus on personalized medicine. This approach customizes medical care based on unique patient attributes, including genetic makeup, daily habits, and surroundings. Its rise is driven by progress in genomics, biotechnology, and data analytics, which facilitates targeted treatments that enhance effectiveness and minimize side effects for patients. For giant-cell arteritis (GCA), personalized medicine offers the benefit of customized therapies, considering individual patient elements like genetic predispositions, immune system profiles, and how the disease presents itself. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit entity, stated that personalized medicines constituted over one-third of the new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023, marking the fourth consecutive year this trend occurred. In 2023, the FDA sanctioned 16 novel personalized therapies specifically designed for rare diseases, representing a substantial rise from six approvals recorded in 2022. Furthermore, the 2023 approvals included seven cancer medications and three treatments targeting a range of other diseases and health conditions. Consequently, the increasing emphasis on personalized medicine is a key driver for the expansion of the giant-cell arteritis market.

    What Segment Categories Shape The Giant-Cell Arteritis Market Segment Landscape?

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Which Trends Are Expected To Impact The Giant-Cell Arteritis Market?

    Leading companies engaged in the giant-cell arteritis market are creating new products, such as biosimilars, to expand available treatments and fulfill the unmet medical requirements of patients. A biosimilar is a biological drug that exhibits high similarity to an already sanctioned biological product, lacking any clinically meaningful distinctions in terms of its safety, purity, and potency. For example, in April 2024, Fresenius SE & Co. KGaA, a healthcare company based in Germany, launched Tocilizumab-aazg in the US for managing chronic autoimmune diseases. This biosimilar is approved for conditions including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval relied on findings from a randomized, double-blind, single-dose, parallel phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity with both US and EU reference tocilizumab across three patient groups.

    Who Are The Companies Operating Across The Giant-Cell Arteritis Market Value Chain?

    Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol‑Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

    Get The Full Giant-Cell Arteritis Market Report:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Where Is The Giant-Cell Arteritis Market Primarily Concentrated By Region?

    North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Giant-Cell Arteritis Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2026, By The Business Research Company

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Small Cell Backhaul Market Report 2026

    https://www.thebusinessresearchcompany.com/report/small-cell-backhaul-global-market-report

    Rare Kidney Diseases Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Giant-Cell Arteritis Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

    Giant-Cell Arteritis Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Size Growth Is Projected For The Giant-Cell Arteritis Market During The Forecast Period 2026–2030?

    The giant-cell arteritis market has demonstrated consistent growth in recent years. It is expected to expand from $1.12 billion in 2025 to $1.18 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.9%. This historical growth can be attributed to an aging population’s growth, the continued reliance on corticosteroid therapy, improvements in rheumatology care, the expansion of hospital-based treatment, and increased disease awareness.

    The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast timeframe is primarily driven by factors such as the approval of biologic drugs, advancements in immunology research, enhanced diagnostic procedures, tailored vasculitis treatments, and the proliferation of specialized clinics. Key developments expected within this period encompass a greater uptake of biologic therapies, an elevated emphasis on prompt and precise diagnosis, a wider application of corticosteroid-sparing treatments, enhanced long-term disease surveillance, and an increasing understanding of how to prevent vision loss.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    Which Economic Or Industry Drivers Are Impacting The Giant-Cell Arteritis Market?

    The giant-cell arteritis market is projected to expand moving forward due to a rising emphasis on personalized medicine. This medical approach entails customizing treatment to align with individual characteristics, such as genetics, lifestyle, and environment. Personalized medicine is gaining prominence because of progress in genomics, biotechnology, and data analytics, which facilitates targeted therapies that improve treatment effectiveness and minimize adverse effects for individuals. For giant-cell arteritis (GCA), personalized medicine can be beneficial by allowing for specific therapies developed from individual patient factors such as genetic predispositions, immune profiles, and disease manifestations. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, indicated that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. In that year, the FDA sanctioned 16 new personalized treatments tailored for rare diseases, representing a notable increase from six approvals in 2022. Furthermore, the approvals in 2023 included seven cancer medications and three treatments for various other diseases and conditions. Consequently, the growing emphasis on personalized medicine is driving the growth of the giant-cell arteritis market.

    What Market Segments Are Evaluated Within The Giant-Cell Arteritis Market?

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    What Trends Are Affecting The Expansion Of The Giant-Cell Arteritis Market?

    Major companies operating in the giant-cell arteritis are focusing on developing new products, such as biosimilars, to expand available treatment options and address the outstanding medical needs of patients. A biosimilar is defined as a biologic drug that is highly comparable to an already approved biological product, exhibiting no clinically relevant differences regarding safety, purity, and potency. For example, in April 2024, Fresenius SE & Co. KGaA, a Germany-based healthcare company, launched Tocilizumab-aazg in the US market for the treatment of chronic autoimmune diseases. This biosimilar received approval for conditions including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was founded on data from a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient groups.

    Who Are The Top Market Participants Influencing The Giant-Cell Arteritis Market?

    Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

    Read the full giant-cell arteritis market report here:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    What Are The Top-Performing Regions Within The Giant-Cell Arteritis Market?

    North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Giant-Cell Arteritis Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

    Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2026, By The Business Research Company

    Monkey Pox Testing Global Market Report

    https://www.thebusinessresearchcompany.com/report/monkey-pox-testing-global-market-report

    Enteric Disease Testing Global Market Report

    https://www.thebusinessresearchcompany.com/report/enteric-disease-testing-global-market-report

    Bowel Management Systems Global Market Report

    https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Giant-Cell Arteritis Market 2026–2030: Forecast Insights for Business Planning

    Global Giant-Cell Arteritis Market 2026–2030: Forecast Insights for Business Planning

    Uncover key drivers, emerging technologies, and competitive movements shaping the giant-cell arteritis market from 2026–2035 with trusted insights from The Business Research Company

    How much larger will the Giant-Cell Arteritis Market be in 2030 compared with 2026?

    The giant-cell arteritis market has shown steady expansion over recent years. It is anticipated to increase from $1.12 billion in 2025 to $1.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.9%. This past growth can be ascribed to factors such as the rise in the aging population, the continued use of corticosteroid therapy, better rheumatology care, the expansion of hospital-based treatment options, and heightened awareness of the disease.

    The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projection period include the approval of new biologic drugs, advancements in immunology research, enhanced diagnostic procedures, tailored vasculitis treatments, and an increase in specialized clinics. Key trends identified for the forecast timeframe encompass a greater uptake of biologic therapies, a heightened emphasis on prompt and precise diagnosis, broader application of corticosteroid-sparing treatments, enhanced long-term disease surveillance, and increasing recognition of methods to prevent vision loss.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    What Drivers Are Guiding Growth Patterns In The Giant-Cell Arteritis Market?

    The giant-cell arteritis market is expected to grow due to a rising focus on personalized medicine. This approach customizes medical treatments according to individual characteristics, such as genetics, lifestyle, and environment. The expansion of personalized medicine is driven by advances in genomics, biotechnology, and data analytics, which enable targeted therapies that boost treatment effectiveness and minimize adverse effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine can facilitate specific therapies based on individual patient factors like genetic predispositions, immune profiles, and disease manifestations. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, stated that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. During 2023, the FDA approved 16 new personalized treatments specifically for rare diseases, marking a significant increase from six approvals in 2022. Furthermore, the 2023 approvals also covered seven cancer medications and three treatments for various other diseases and conditions. Therefore, the growing emphasis on personalized medicine is a key factor driving the growth of the giant-cell arteritis market.

    Which Segments Are Driving Activity In The Giant-Cell Arteritis Market?

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Which Trends Are Influencing The Performance And Direction Of The Giant-Cell Arteritis Market?

    Leading companies involved in giant-cell arteritis are creating novel products, including biosimilars, to broaden available treatments and cater to patients’ outstanding medical requirements. A biosimilar is a biological medicine that closely resembles an existing approved biological product, demonstrating no significant clinical variations in its safety, purity, or potency. For example, Fresenius SE & Co. KGaA, a healthcare firm based in Germany, introduced Tocilizumab-aazg in the US in April 2024 for the management of chronic autoimmune conditions. This particular biosimilar has received approval for treating conditions like rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The approval was granted following data from a randomized, double-blind, single-dose, parallel phase 1 trial that assessed its pharmacokinetics, safety, and immunogenicity against both US and EU reference tocilizumab across three distinct patient cohorts.

    Which Key Players Are Driving Competition In The Giant-Cell Arteritis Market?

    Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    Which Region Currently Holds The Largest Share Of The Giant-Cell Arteritis Market?

    North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Giant-Cell Arteritis Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

    Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2026, By The Business Research Company

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Small Cell Backhaul Market Report 2026

    https://www.thebusinessresearchcompany.com/report/small-cell-backhaul-global-market-report

    Rare Kidney Diseases Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Is The Long-Term Forecast For The Global Giant-Cell Arteritis Market Growing At 4.6% CAGR?

    What Is The Long-Term Forecast For The Global Giant-Cell Arteritis Market Growing At 4.6% CAGR?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What CAGR And Valuation Are Anticipated For The Giant-Cell Arteritis Market?

    The market size of giant-cell arteritis has seen a powerful growth recently. It’s projected to expand from $1.07 billion in 2024 to $1.12 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.0%. The growth during the past period can be credited to factors such as epidemiological research, genetic advancements, the increasing use of biologics, enhancement in diagnostic methods, and the progression of targeted therapies and biologics.

    In the coming years, the market size of giant-cell arteritis is anticipated to sustain a steady growth. It is predicted to inflate to $1.34 billion in 2029, with a 4.6% compound annual growth rate (CAGR). Factors contributing to the growth during the forecast period include improved diagnosis rates, an aging demographic, enhanced healthcare spending, active patient advocacy, and extending into new geographical areas. The forecast period is also expected to see key trends such as enhancement in the identification and validation of biomarkers, the advent of therapies targeting distinctive molecular pathways, adoption of sophisticated imaging methods, innovations in drug delivery, and the application of AI algorithms for predictive analysis.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    What Are The Primary Factors Supporting The Giant-Cell Arteritis Market Expansion?

    The surge in personalized medicine is seen as a significant factor propelling the expansion of the giant-cell arteritis market. The concept of personalized medicine ensures medical treatments are tailored according to individual characteristics, such as genetic makeup, lifestyle, and environment. The growth of personalized medicine is fueled by advancements in genomics, biotechnology, and data analytics, which facilitate targeted therapies enhancing treatment effectiveness and reducing negative impacts. In the case of giant-cell arteritis (GCA), providing personalized treatments based on factors like genetic predispositions, immune profiles, and disease expressions can be beneficial. The Personalized Medicine Coalition (PMC), an American non-profit organization, reported in February 2024 that personalized medicines made up more than one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for four consecutive years, up to 2023. During 2023, the FDA endorsed 16 new custom-tailored treatments for rare diseases, an upturn from six approvals in 2022. Seven cancer medicines and three therapies for various other diseases were among the approved treatments in 2023. Hence, the escalating focus on personalized medicine is instrumental in driving the evolution of the giant-cell arteritis market.

    Which Segments Define The Structure Of The Giant-Cell Arteritis Market?

    The giant-cell arteritismarket covered in this report is segmented –

    1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin

    2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action

    3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin

    What Strategic Shifts And Innovations Are Influencing The Giant-Cell Arteritis Market?

    Leading businesses in the field of giant-cell arteritis are innovating and releasing new offerings like biosimilars to broaden therapeutic avenues and fulfill the unaddressed medical needs of their patients. Biosimilars are biologic medicines that closely mirror already approved biological medications, possessing no significant clinical disparities in safety, purity, and effectiveness. For example, in April 2024, Fresenius SE & Co. KGaA, a health care company based in Germany, introduced Tocilizumab-aazg in the US, targeting chronic autoimmune diseases. This biosimilar is greenlit for ailments including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The approval was granted based on results from a phase 1 trial where it was randomized, double-blind, single-dose, and parallel to compare its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient demographics.

    Who Are The Primary Market Leaders In The Giant-Cell Arteritis Market?

    Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    What Regional Factors Are Accelerating Growth In The Giant-Cell Arteritis Market?

    North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

    Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2025, By The Business Research Company

    Cell Culture Consumables And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

    Stem Cell Cord Blood Banking Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

    Induced Pluripotent Stem Cell Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Giant-Cell Arteritis Market Trends and Growth Analysis 2025–2029

    Global Giant-Cell Arteritis Market Trends and Growth Analysis 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Anticipated Size Of The Giant-Cell Arteritis Market Over The Five-Year Period 2025–2029?

    The giant-cell arteritis market has experienced robust expansion over recent years. It is anticipated to increase from $1.07 billion in 2024 to $1.12 billion in 2025, showing a compound annual growth rate (CAGR) of 5.0%. Historically, this expansion can be ascribed to elements such as epidemiological studies, genetic insights, the increasing uptake of biologics, enhanced diagnostic techniques, and the progression of targeted therapies and biologics.

    The giant-cell arteritis market size is expected to experience steady expansion in the upcoming years. It is projected to reach $1.34 billion in 2029, with a compound annual growth rate (CAGR) of 4.6%. This increase during the forecast period is attributable to factors like rising diagnosis rates, an aging population, increasing healthcare expenditure, enhanced patient advocacy, and market expansion into new geographic regions. Significant trends anticipated for the forecast period include progress in biomarker identification and validation, the development of treatments targeting specific molecular pathways, the adoption of advanced imaging techniques, innovations in drug delivery, and the use of AI algorithms for predictive analytics.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    Which Drivers Are Supporting Growth Of The Giant-Cell Arteritis Market?

    An increasing focus on personalized medicine is anticipated to drive the expansion of the giant-cell arteritis market moving forward. Personalized medicine involves customizing medical care to match individual characteristics, such as genetics, lifestyle, and environmental factors. The adoption of personalized medicine is growing due to advancements in genomics, biotechnology, and data analytics, which facilitate targeted therapies that enhance treatment effectiveness and minimize adverse reactions for individuals. In the context of giant-cell arteritis (GCA), personalized medicine offers the potential for tailored treatments based on unique patient factors like genetic predispositions, immune profiles, and specific disease manifestations. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, reported that personalized medicines comprised over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. During that year, the FDA approved 16 new personalized treatments specifically for rare diseases, representing a significant increase from six approvals recorded in 2022. Furthermore, the approvals in 2023 included seven cancer medications and three treatments for various other diseases and conditions. Therefore, the heightened emphasis on personalized medicine is fueling the growth of the giant-cell arteritis market.

    Which Key Segments Fueling The Giant-Cell Arteritis Market?

    The giant-cell arteritismarket covered in this report is segmented –

    1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin

    2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action

    3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin

    Which Competitive Trends Are Defining The Giant-Cell Arteritis Market Structure?

    Leading companies engaged in the giant-cell arteritis sector are developing novel products, including biosimilars, to expand treatment possibilities and address patients’ unmet medical needs. A biosimilar is defined as a biological drug that is remarkably similar to an already approved biological product, showing no clinically significant disparities in terms of safety, purity, and potency. For example, in April 2024, Fresenius SE & Co. KGaA, a healthcare company based in Germany, introduced Tocilizumab-aazg in the US for the treatment of chronic autoimmune diseases. This biosimilar has received approval for conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was founded on data from a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient cohorts.

    Which Leading Companies Dominate The Giant-Cell Arteritis Market Share?

    Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    How Do Regional Market Performances Compare Within The Giant-Cell Arteritis Industry?

    North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Giant-Cell Arteritis Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

    Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2025, By The Business Research Company

    Cell Culture Consumables And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

    Stem Cell Cord Blood Banking Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

    Induced Pluripotent Stem Cell Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Giant-Cell Arteritis Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Giant-Cell Arteritis Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theGiant-Cell Arteritis Market?

    The expansion of the giant-cell arteritis market is anticipated to be driven by the increasing stress on personalized medicine. This approach to treatment, which considers each individual’s genetics, lifestyle, and environment, is growing thanks to advancements in genomics, biotechnology, and data analytics. These techniques allow for targeted therapies, which enhance treatment efficiency, decrease the risk of side effects for patients, and have the potential to improve giant-cell arteritis (GCA) management. These custom treatments can be formulated based on an individual’s specific genetic predispositions, immune profiles, and disease symptoms. The Personalized Medicine Coalition (PMC), a not-for-profit organization based in the U.S., reported in February 2024 that over a third of new medicines approved by the U.S. Food and Drug Administration (FDA) in 2023 were personalized medicines, marking the fourth successive year with such results. These included 16 new personalized treatments for rare diseases (up from six approvals in 2022), seven cancer drugs, and three treatments for a variety of other health conditions. Consequently, the growing emphasis on personalized medicine is encouraging the progression of the giant-cell arteritis market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    #What Growth Opportunities Will Drive the Giant-Cell Arteritis Market’s CAGR Through 2034?

    Over the past few years, the market size for giant-cell arteritis has seen substantial growth. The market is predicted to expand from $1.07 billion in 2024 to $1.12 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.3%. Factors including epidemiological research, advancements in genetics, the rising use of biologics, improved diagnostic methods, and the progress in targeted treatments and biologics have all contributed to the growth witnessed during the historical period.

    Anticipated persistent expansion is on the horizon for the giant-cell arteritis market. The market value is predicted to reach $1.36 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The projected surge during this duration is due to contributing factors such as higher diagnosis rates, an aging demographic, escalating health care expenditure, patient advocacy, and penetrating new geographical territories. The exciting trends during the forecast period encompass breakthroughs in pinpointing and validating biomarkers, the formulation of therapies that target precise molecular routes, incorporation of state-of-the-art imaging techniques, revolutions in drug conveyance, and the application of artificial intelligence for anticipatory analytics.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

    What Are the Current Market Growth and Trends in theGiant-Cell Arteritis Market That Industry Players Should Watch?

    Principal businesses in the giant-cell arteritis market are focusing on creating novel products like biosimilars to broaden the range of treatment alternatives and answer the unserved health needs of patients. Biosimilars, which are biological drugs that exhibit a high level of similarity to already authorized biological products, exhibit no significant clinical variations concerning safety, efficacy, and potency. For example, in April 2024, the German healthcare firm Fresenius SE & Co. KGaA rolled out Tocilizumab-aazg in the US to treat chronic autoimmune diseases. Approved for medical conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis, the biosimilar product’s authorization was based on information from a randomized, single-dose, double-blind, parallel phase 1 trial contrasting its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient demographics.

    What Are the Major Market Players Making an Impact on theGiant-Cell Arteritis Market Growth?

    Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    How Are the Key Segments of the Giant-Cell Arteritis Market Driving Opportunities and Innovations?

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

    What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theGiant-Cell Arteritis Market?# Market Expansion?

    North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2025, By The Business Research Company:

    Cell Based Assays Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

    Cell Culture Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

    Stem Cell Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Growth Opportunities and Trends in the Giant-Cell Arteritis Market: Key Insights for 2025-2034

    Growth Opportunities and Trends in the Giant-Cell Arteritis Market: Key Insights for 2025-2034

    Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

    What fueled the previous growth in the giant-cell arteritis market?

    In recent times, the market size of giant-cell arteritis has experienced substantial growth. The forecast suggests an increase from $1.07 billion in 2024 to $1.12 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.3%. Various factors contribute to this historic growth, including epidemiological research, genetic discoveries, a growing preference for biologics, advances in diagnostic procedures, and the evolution of targeted treatments and biologics.

    What will be the giant-cell arteritis market size in the future?

    Expectations for the market size of giant-cell arteritis indicate consistent expansion over the next years. By 2029, the market is expected to reach $1.36 billion, with a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period can be linked to a variety of factors, including improved diagnosis rates, an older population, increased health care spending, patient advocacy, and market expansion into novel geographic areas. Expectations for major trends within this period encompass advancements in biomarker identification and validation, the development of therapy targeting specific molecular pathways, the adoption of cutting-edge imaging technologies, advancements in drug delivery, and the implementation of artificial intelligence for predictive analytics.

    Get your giant-cell arteritis market report here!

    https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

    What main drivers are fueling expansion in the giant-cell arteritis market?

    The giant-cell arteritis market is set to grow due to the increasing focus on personalized medicine. This approach to treatment, which is based on individual characteristics such as genetics, lifestyle, and environment, is on the rise, fueled by advancements in genomics, biotechnology, and data analytics. Such advancements facilitate the development of targeted therapies that can enhance the effectiveness of treatment and minimize adverse effects. As far as giant-cell arteritis (GCA) is concerned, personalized medicine can deliver targeted therapies tailored to various patient factors like genetic predispositions, immune profiles, and disease manifestations. The Personalized Medicine Coalition (PMC), a non-profit organization based in the U.S., revealed in February 2024 that over a third of new drug approvals by the U.S. Food and Drug Administration (FDA), for the fourth year running, were personalized medicines in 2023. That year, the FDA gave the green light to 16 new personalized treatments for rare diseases, a significant rise from just six in 2022. The approvals in 2023 also included seven cancer drugs and three treatments for various other medical conditions. Thus, the burgeoning emphasis on personalized medicine is fuelling the growth of the giant-cell arteritis market.

    What key areas define the segmentation of the global giant-cell arteritis market?

    The giant-cell arteritis market covered in this report is segmented –

    1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

    2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

    3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

    Subsegments:

    1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

    2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

    3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

    4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

    Who are the dominant players expanding their reach in the giant-cell arteritis market?

    Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

    What key trends are currently impacting the giant-cell arteritis market’s development?

    Leading organizations within the giant-cell arteritis market are innovating new offerings including biosimilars, in an effort to broaden treatment methods and cater to the unaddressed needs within patient care. Biosimilars refer to biologic medicines that closely resemble an approved biological product, with no major discrepancies concerning safety, purity, and potency. The healthcare company based in Germany, Fresenius SE & Co. KGaA, in April 2024, introduced a new product called Tocilizumab-aazg intended for patients with chronic autoimmune diseases within the US market. This biosimilar has gained approval for treating diseases like rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), as well as giant cell arteritis. Approval was granted based on evidence derived from a randomized, double-blind, single-dose, parallel phase 1 trial. Comparison of its pharmacokinetics, safety, and immunogenicity was done against both US and EU reference tocilizumab across three different patient groups.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

    Which regions are emerging as leaders in the giant-cell arteritis market?

    North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Cell Based Assays Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

    Cell Culture Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

    Stem Cell Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: